Nuvation Bio Inc.
$5.12
▼
-2.22%
2026-04-21 08:31:00
www.nuvationbio.com
NYQ: NUVB
Explore Nuvation Bio Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.77 B
Current Price
$5.12
52W High / Low
$9.75 / $1.57
Stock P/E
—
Book Value
$0.88
Dividend Yield
—
ROCE
-41.57%
ROE
-53.18%
Face Value
—
EPS
$-0.6
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
298
Beta
1.61
Debt / Equity
21.9
Current Ratio
6.95
Quick Ratio
6.81
Forward P/E
-31.72
Price / Sales
25.42
Enterprise Value
$1.14 B
EV / EBITDA
-5.38
EV / Revenue
18.07
Rating
Strong Buy
Target Price
$12.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
| 2. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
| 3. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 4. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 7. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 41.87 M | 13.12 M | 4.83 M | 3.08 M | 5.71 M |
| Operating Profit | -34.04 M | -56.43 M | -63.59 M | -59 M | -53.94 M |
| Net Profit | -36.59 M | -55.79 M | -59.01 M | -53.24 M | -49.45 M |
| EPS in Rs | -0.11 | -0.16 | -0.17 | -0.15 | -0.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 62.9 M | 7.87 M | 0 M | 0 M |
| Operating Profit | -213.06 M | -167.56 M | -99.82 M | -119.73 M |
| Net Profit | -204.63 M | -567.94 M | -75.8 M | -104.2 M |
| EPS in Rs | -0.59 | -1.64 | -0.22 | -0.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 594.82 M | 540.63 M | 621.48 M | 672.14 M |
| Total Liabilities | 289.11 M | 76.84 M | 16.36 M | 17.07 M |
| Equity | 305.72 M | 463.79 M | 605.12 M | 655.08 M |
| Current Assets | 571.52 M | 526.25 M | 616.43 M | 667.32 M |
| Current Liabilities | 82.23 M | 58.24 M | 13.97 M | 13.16 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -173.43 M | -130.41 M | -68 M | -96.11 M |
| Investing CF | 99.52 M | 122.7 M | 8.92 M | 63.46 M |
| Financing CF | 202.53 M | 0.33 M | 0.63 M | 1.33 M |
| Free CF | -181.78 M | -130.57 M | -68.07 M | -96.48 M |
| Capex | -8.35 M | -0.16 M | -0.07 M | -0.37 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -649.24% | 27.25% | — | — |
| Profit Margin % | -7213.76% | — | — | — |
| Operating Margin % | -2128.25% | — | — | — |
| Gross Margin % | 10.1% | — | — | — |
| EBITDA Margin % | -7200.75% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.